NO. 1726 P. 1/6

RECEIVED CENTRAL FAX CENTER

JAN 2 7 2005

Under the Panerwork Reduction Act of 1989 TRANSMITTAL FORM (no be used for all correspondence after initial Total Number of Pages in The Submission	Application Number Filing Date First Named Inventor Art Unit Examiner Name	August Manfred V. Balas	rademark Office: formation unless to	et al.
ENCLOSURES (Check all that apply)				
Fee Transmittal Form Fee Attached Amendment/Repty After Fina Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Repty to Missing Parts/ Incomplete Application Repty to Missing Parts/ Incomplete Application Repty to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Patition to Convert to a Provisional Application Power of Altorney, Revocation Change of Correspondence of Co	oh Address	After / Appea of App Appea (Appea (Appea) Propri	Allowance Communication to TC al Communication to Board peals and Interferences al Communication to TC al Notice, Brief, Reply Brief) etary Information a Letter Enclosure(s) (please Identify):
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm Name AVENTIS PHARMAC Signature Printed name Joseph D. Rodsi Date January 27, 2005	EUTICALS INC.	Reg, No.	47,038	
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-672-9305 ; Total No. of Pages Transmitted: 6) Signature				
Typed or printed name Paul Irvine			Date	January 27, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, abound be sent to the Chief Information Orders, U.S. Patient and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandra, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandra, VA 22313-1450.

BEST AVAILABLE COPY

DEAV2000/A043 US NP1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of SCHUDOK et al.

Examiner:

V. Balasubramanian

Art Unit:

1624

Application No.: 10/634,827

August 6, 2003

Title:

Filed:

MALONAMID AND MALONAMIC

ESTER DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY, THEIR PREPARATION, AND THEIR

USE

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on

RECEIVED **CENTRAL FAX CENTER**

REPLY TO THE RESTRICTION REQUIREMENT

JAN 2 7 2005

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

This paper is in response to the Office Action dated December 27, 2004 ("the Action"), in which a restriction requirement was issued in connection with the above-identified patent application. Applicants respectfully request reconsideration of the restriction requirement in view of the following remarks.